Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02989285 : Identification and Quantification of HIV CNS Latency Biomarkers
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- HIV-infected

- Aged >18 years

- On HAART with viral load suppression (<50 copies / ml) in both plasma and CSF for at
least 6 months

- Able to provide informed consent

Exclusion Criteria:

- Non-HIV related neurological disorder or active CNS opportunistic infection as
assessed by full blood count, electrolytes, creatinine, glucose, liver function
tests, venereal disease reaction level (VDRL), MRI brain scan and CSF analyses for
cell count, protein, glucose, culture, VDRL and cryptococcal antigen

- Psychiatric disorders on the psychotic axis, current major depression, current
substance use disorder and/or 12 month history of severe substance use disorder

- Active Hepatitis C co-infection

- History of severe traumatic brain injury (post-traumatic amnesia (PTA) duration>1
day) or loss of consciousness > 30 minutes from other cause (e.g., hypoxic brain
injury)

- Non-proficient in English
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02989285      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740